Not sure what the price might could get to and that's aside from my opinion that I don't expect AVXL results that would not elicit an additional trial. I feel they use the "genetic" mask for an excuse if their results show a trend but not stat significance. I don't even feel like getting started though. I wish them the best. It's another stock where at the right price it might be worth the gamble for some (not for me however). I think they have a better shot at Rett than larger indications even if they aren't first to market for that even. From a share price perspective, it could be a shame that AD will read out before Rett. AD failure would crater the price and at that point I might consider buying for potential positive Rett news next year. Not sure what you mean about the "half way" thing at the end of your post. If their trial is adequately blinded, then no one will know. JMHO
News 
Market Data 
Discover 
